Figures computed from official regulatory filings — .
Ownershipinsiders 4.47% · institutions 38.49%
In EUR · as of Oct 19, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for ADVICENNE only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and safe treatments for rare renal diseases in France and internationally. It offers Sibnayal for the treatment of metabolic disorders. The company also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizures. Advicenne S.A. was incorporated in 2007 and is headquartered in Paris, France.
Market information source · Oct 19, 2026
Open-market timeline · full history
2 buys2 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| ADVICENNE SA | Buy | $271.5K | conv 68First in 12mo |
| AMF |
| Didier Laurens | Award | $58.7K | AMF |
| BPIFRANCE INVESTISSEMENT SAStrack record | Award | $1.2M | AMF |
| CEMAG INVEST SAS | Award | $3.7M | AMF |
| BPIFRANCE INVESTISSEMENT SAStrack record | Award | $1M | AMF |
| PROMONTOIRES société par actions simplifiée | Buy | $105.1K | conv 51First in 12mo | AMF |
| BPIFRANCE INVESTISSEMENT SAStrack record | Sell | $23.8 | AMF |
| BPIFRANCE INVESTISSEMENT SAStrack record | Sell | $14.3 | AMF |